The effect of long-term high-intensity statin therapy on coronary atherosclerosis among patients with acute ST-segment elevation myocardial infarction (STEMI) is unknown. The aim of this study was to quantify the impact of high-intensity statin therapy on plaque burden, composition, and phenotype in non-infarct-related arteries of STEMI patients undergoing primary percutaneous coronary intervention (PCI).
Introduction
Coronary atherosclerosis is a chronic inflammatory disease, which may go undetected for decades before it gives rise to disease manifestations such as stable, obstructive coronary artery disease, or acute coronary syndromes (ACS). 1 Statin therapy effectively reduces cardiovascular events in the setting of primary and secondary prevention, with a particular benefit occurring early after treatment initiation in ACS patients. 2 High-intensity rosuvastatin therapy has been shown to more effectively lower LDL-C and increase HDL-C compared with other statins. 3 Insights from intracoronary imaging studies suggest that statins result in atheroma regression in patients with stable, non-obstructive coronary artery disease. 4, 5 Patients with STEMI are at high risk for recurrent atherothrombotic events, which is related to multifocal disease with a high prevalence of vulnerable plaques, 6, 7 typically extending beyond the culprit site due to widespread inflammation in other plaques including increased protease activity. 8 The primary hypothesis of the present study was that coronary atherosclerosis regression can be achieved in the presence of the high-intensity rosuvastatin therapy (40 mg daily) in the proximal segments of non-infarct-related arteries (IRA) within 13 months. Due to the importance of plaque phenotype for future cardiovascular events, there is an interest in the study of changes in plaque composition in response to high-intensity statin therapy. The use of radiofrequency intravascular ultrasonography (RF-IVUS) has been validated for the detection of a necrotic core 9 and plaque characterization 10 based on ex vivo histological analyses, providing the means for serial in vivo assessment of plaque composition and phenotype. Therefore, the secondary hypothesis of this study was that highintensity rosuvastatin therapy results in a reduction of RF-IVUS defined necrotic core and a decrease in the frequency RF-IVUS defined thin cap fibroatheromas (TCFA).
Methods

Study design
Integrated biomarker imaging study (IBIS 4) (NCT00962416) is a prospective cohort study nested into the COMFORTABLE-AMI, a trial which compared the safety and efficacy of biolimus-eluting stents with bare metal stents in 1161 STEMI patients undergoing primary PCI at 11 international centres. 11, 12 A total of 103 patients were enrolled in this intracoronary imaging study at five predefined centres using serial IVUS and RF-IVUS investigations to quantify changes in atherosclerotic plaque characteristics in non-IRA under long-term high-intensity statin therapy. Patients enrolled in the clinical trial were screened for clinical and anatomic feasibility to undergo the serial intracoronary imaging protocol. All the patients provided written informed consent, and the study was approved by the institutional review boards of all participating centres.
Patient population
Patients were considered for enrolment if they were included in the COMFORABLE-AMI trial and fulfilled the following additional criteria: age ,90 years, preserved renal, and liver function, haemodynamic stability allowing the repetitive administration of nitroglycerine, TIMI flow ≥2 of the IRA at the completion of primary PCI, and a coronary anatomy suitable for intracoronary imaging in two major proximal coronary arteries in the absence of a lesion qualifying for treatment (stenosis .50%). Intracoronary imaging was directed at the non-treated proximal part (50 mm) of non-IRA. The inclusion was independent of the lipid status and intake of pre-existing lipid-lowering therapy. All the patients received treatment with rosuvastatin at an initial dose of 20 mg once daily during the first 2 weeks to assess compliance and adverse effects followed by 40 mg once daily for the remainder of the follow-up period.
Procedures Intravascular ultrasonography at baseline
Following successful primary PCI (i.e. TIMI flow ≥2), the infarct-related vessel was imaged first (data not reported here), followed by intracoronary imaging of the proximal 50 mm of the two non-IRA. The region of interest (ROI) was selected between two anatomical landmarks (distal: sidebranch, proximal: LM bifurcation or ostium of the RCA). A 20-MHz ultrasound catheter (Eagle Eye, Volcano Cooperation, Rancho Cordova, CA) was advanced beyond the distal landmark and a motorized pullback at a speed of 0.5 mm/s was performed after the administration of 200 mg intracoronary nitroglycerine. Images were acquired with 30 frames per second and recorded on a DVD. Recordings were sent to an independent Core Laboratory (Cardialysis B.V., Rotterdam, The Netherlands) for quality control; only if pre-specified criteria were met, the runs were considered for analysis.
Intravascular ultrasonography at follow-up
All the patients were scheduled for intracoronary imaging follow-up at 13 months. Prior to the imaging, the operator was provided with a summary information on the distal and proximal landmarks used at baseline to achieve a maximal overlap of the acquired pullbacks. If a patient underwent symptom-driven repeat angiography prior to the 13 months visit, the intracoronary imaging protocol was allowed to be repeated as early as 10 months after primary PCI but not earlier. In case of an intermittent revascularization of a previously imaged ROI, it was recommended to perform IVUS prior to revascularization at any timepoint if technically and clinically feasible.
Intravascular ultrasonography analysis
Only after availability of the serial IVUS recordings, an independent person randomly allocated a code to the baseline and follow-up pullbacks in order to ensure blinding of the analysts to the temporal sequence of paired images. An analyst not involved in the actual analysis evaluated the quality of the recordings and was responsible for deleting the procedure date and any other identifying information. The statistician was provided with the coding list to unblind the temporal sequence and to perform the data analysis only after the entire imaging analysis had been completed and the statistical analysis was at an advanced stage. A technician assessed the largest common ROI available from the two serial recordings with the help of a dedicated matching software and identified as much common matching points within the pullbacks (e.g. sidebranches, calcifications). Within the matched ROI, the lumen and the external elastic membrane were measured in every frame ( 0.4 mm) using a validated software (QIVUS, Medis, Leiden, The Netherlands).
Intravascular ultrasonography end-points
Serial IVUS data were derived from the matched ROI and for the most diseased 10 mm segment at baseline. The primary end-point of the study was the change in per cent atheroma volume (PAV). The calculation of all IVUS and RF-IVUS end-points is shown in Supplementary material online, Appendix.
Radiofrequency intravascular ultrasonography
The secondary end-point of the study was the change in RF-IVUS defined per cent volume necrotic core. The plaque composition analysis using IVUS was obtained by processing the RF signals in a dedicated offline software (QIVUS, Medis, Leiden, The Netherlands). In this software Volcano's proprietary virtual histology (VH w ) IVUS analysis technology is integrated. This results in the characterization of four different tissue types: necrotic core (red), dense calcium (white), fibro-fatty (light green), and fibrous (green). In addition, a lesion type analysis was performed according to the PROSPECT study methodology. 13, 14 The detailed lesion assessment is explained in Supplementary material online, Appendix.
Statistical analysis
Baseline and medication characteristics were analysed with Pearson x 2 , Wilcoxon rank-sum, Fisher's exact, and t-tests as appropriate. Lipid values were reported as median and inter-quartile range (IQR). Change in lipid values was analysed with paired patient-level data with Wilcoxon signed-rank tests. Absolute changes were reported and tested except, if necessary to fulfil symmetry assumption, analysis was done on the log-transformed values and relative changes were reported and tested. In most patients, IVUS data were available for two non-IRA at baseline and 13-month follow-up. The absolute change from baseline to follow-up was derived at vessel level as end-point (FUP) minus end-point (BL) such that a negative value indicates a decrease over time. The changes were analysed with linear mixed models with patient as random intercept to account for the non-independence of end-points from the same patient. Two-sided P-values quantify the statistical evidence that the absolute change is different from zero. The results of the stratified analysis in Figure 3 is based on the same method but an additional interaction P-value is provided to quantify the evidence that change was different between the strata. To assess the association between changes in LDL-C and HDL-C and change in PAV (Figure 4) , we stratified the patients into four groups with a quartile split on the 
Results
Patient characteristics
Between September 2009 and January 2011, 103 (out of 602 STEMI patients enrolled into the COMORTABLE AMI trial at all intracoronary imaging sites) underwent primary PCI and IVUS and RF-IVUS of both non-IRA. The flow chart in Figure 1 provides detailed information on the number of patients and vessels included into the final analysis. For the final serial IVUS and RF-IVUS analysis, a total of 82 patients with 146 vessels were available. Baseline clinical characteristics were similar for patients undergoing serial intracoronary imaging and those not undergoing serial imaging ( Table 1) . Patients enrolled into the intracoronary imaging study-as opposed to those participating in the clinical trial only-were younger, more likely male, more obese, and had a lower frequency of hyperlipidaemia compared with those participating in the clinical follow-up protocol (Supplementary material online, Table S1 ). Cardiovascular medication and statin therapy is summarized in Table 2 . A total of 8 (10%) patients were on statin treatment at the timepoint of study inclusion with none of them receiving high-intensity statin therapy.
Lipid profile
The lipid profile at the timepoint of inclusion, 30, and 13 months is summarized in Figure 2 . HDL-C levels increased from 1.10 mmol/L (IQR: 0.96-1.26) to 1.20 mmol/L (IQR: 1.00-1.48) (P , 0.0001), and LDL-C decreased from a from 3.29 mmol/L (IQR: 2.78-3.75) to 1.89 mmol/L (IQR: 1.60-2.32) at 13 months (P , 0.0001). A total of 44% of patients achieved a guideline-recommended LDL-C level of ≤1.8 mmol/L at a 13-month follow-up. Table 3 summarizes the results of the serial changes in IVUS parameters. After 13 months of high-intensity rosuvastatin therapy, the primary IVUS end-point change in PAV amounted to 20.90% (CI: 21.56 to 20.25%; P ¼ 0.007) with a reduction from 43.95 + 9.66% at baseline to 43.02 + 9.82% at follow-up. The reduction within the worst 10 mm was more pronounced as shown in Table 3 ; 74% of patients had at least one vessel with disease regression, 54% of patients showed regression in both vessels, and 65% of patients had a mean PAV reduction (i.e. mean PAV change ,0). In stratified analyses of the primary IVUS end-point change in PAV (Figure 3) , the decrease in PAV was consistent in most subgroups with the exception of patients with diabetes mellitus, in whom a less pronounced reduction of PAV was observed compared with patients without diabetes (P for interaction ¼ 0.054).
Ultrasonography findings
The association between baseline LDL-C and HDL-C and their change over 13 months with the change in PAV is shown in Figure 4 . When stratifying patients into quartiles according to LDL-C reduction or HDL-C increase, a significant linear trend was observed for the reduction in per cent atheroma. The change in PAV was independent of baseline HDL-C and LDL-C levels ( Figure 4) . To eliminate concerns of bias introduced by imaging of more than one vessel per patient, we performed a sensitivity analysis, which only used data from one vessel in case there were two, giving preference to LAD over LCX over RCA. Results remained essentially the same (PAV reduction 21.07%, CI: 21.86 to 20.28%, P ¼ 0.009) (Supplementary material online, Table S2 ).
Radiofrequency intravascular ultrasonography defined tissue composition
Serial RF-IVUS data are summarized in Table 4 . There was no significant change in the secondary end-point of RF-IVUS defined per cent necrotic core between baseline and follow-up (20.05%; CI: 21.05 to 0.96%; P ¼ 0.93), whereas the proportion of calcified tissue components increased (+1.28%; CI: 0.66 to 1.90%; P , 0.0001) and fibrous tissue components decreased (21.38%; CI: 22.28 to 20.47%; P ¼ 0.003). As an exploratory analysis, we calculated the absolute changes in tissue composition (Supplementary material online, 
Radiofrequency intravascular ultrasonography defined lesion phenotype
Serial lesion-related RF-IVUS at baseline and 13 months are provided in Table 5 . In the entire proximal, non-infarct-related vessel segments, 164 atherosclerotic lesions were observed at baseline (2 per patient, 1 per analysed non-IRA), of which RF-IVUS defined TCFA were most frequent (n ¼ 124 (75%). At 13-month follow-up, 158 lesions were observed (7 resolved, 1 new lesion), with 116 (70%) RF-IVUS defined TCFAs. A total of 17 RF-IVUS defined TCFAs observed at baseline converted into lower risk lesion types at follow-up and nine TCFAs were newly formated (7 from a ThCFA lesion and 1 from a PIT lesion), corresponding to a change in proportion of TCFA from 75% at baseline to 70% at 13 months (P ¼ 0.15).
Discussion
This serial intracoronary imaging study investigated the effects of high-intensity rosuvastatin therapy on coronary atherosclerosis in terms of plaque burden, RF-IVUS defined plaque composition and phenotype in the proximal segments of non-IRA of patients presenting with acute STEMI ( Figure 5 ). In the present study, high-intensity rosuvastatin therapy over 13 months reduced mean plasma LDL-C achieving a treatment target of ,1.8 mmol/L in 44% of patients. Serial intracoronary imaging revealed that high-intensity lipid-lowering therapy resulted in regression of coronary atherosclerosis in the proximal segments of non-IRA among STEMI patients. Two previous studies have reported regression of coronary atherosclerosis among lower risk patients with stable, non-obstructive coronary artery disease under highintensity rosuvastatin therapy. 4, 5 The results of the present study investigating high-risk STEMI patients using multi-vessel intracoronary imaging and analysis by a different Core Laboratory yielded similar results as those observed in the Effect of very high-intensity statin therapy on regression of coronary atherosclerosis (ASTEROID) trial. In this trial, the reduction in PAV amounted to 20.98 + 3;15% and total atheroma volume was reduced by 214.7 + 25.7 mm 3 ; despite a longer duration of therapy (13 vs. 24 months) and lower on target lipid levels. Of note, atheroma burden in the present study was in average higher ( 10%) reflecting the higher risk population. Despite the exclusion of patients with obstructive coronary artery disease of non-IRA, this observation underscores the high atherosclerotic disease burden observed in the proximal segments of non-IRA among STEMI patients. Although subgroup analyses were not pre-specified, there was no statistical heterogeneity concerning the change in PAV across major subgroups (Figure 3) . It is of interest that the more pronounced changes in LDL-C reduction and HDL-C increase over 13 months resulted in larger changes of PAV reduction (Figure 4) , which was not the case for baseline LDL-C and HDL-C (Figure 4) . This observation as well as the results of a large meta-analysis of statin therapy, which reported a significant reduction in vascular events For descriptive purposes the mean + SD over all vessels is reported for baseline and follow-up. Two-sided P-values to test if change is different from 0 are from linear mixed models (patient as random intercept). TAV, total atheroma volume; PAV, per cent atheroma volume. independent from the baseline LDL-C levels, 15 reinforce the benefit of high-intensity statin therapy in STEMI patients independent of the baseline lipid levels.
Radiofrequency intravascular ultrasonography defined changes in plaque composition
In two large-scale clinical outcome trials, the use of high-intensity statin therapy was associated with a significant decrease in cardiovascular events compared with the standard statin therapy. 2, 16 The improved clinical outcome has not been directly attributed to atherosclerosis regression so far, and it remains unclear whether the beneficial effects of lipid-lowering therapy are related to other effects than reduction in plaque burden such as changes in plaque composition or plaque phenotype. 17 Despite significant atheroma regression, no change in RF-IVUS defined per cent necrotic core was observed during serial examinations under high-intensity statin therapy. Two previous studies investigating serial changes in a necrotic core were performed in patients with stable, non-obstructive coronary artery disease. The integrated biomarker imaging study 2 study (IBIS-2) 18 using conventional doses of lipid therapy showed an increase in per cent necrotic core (2.5 + 9.6%) throughout 12 months. 18 Similarly, the RF substudy of SATURN, 19 which recorded a lower proportion of a necrotic core at baseline (12.3%) compared with the present STEMI population in 71 patients, observed an increase of 1.9% in a necrotic core (P , 0.001) despite high-intensity statin therapy and a significant reduction of the atheroma volume. Available evidence therefore suggests that high-intensity statin therapy does not reduce a necrotic core burden as determined by RF-IVUS during an observation period of 13 months, which is relatively short compared with otherwise permanent treatment recommendations for secondary prevention. Statin therapy has been reported to reduce lipid content, oxidized LDL, and inflammatory cells in tissue extracted by means of atherectomy. 20 In contrast, we did not observe a reduction in RF-IVUS defined lipid-rich tissue (fibro-fatty or necrotic core) but rather an increase in calcium. An increase in calcium was previously noted independent of statin dose using investigation by coronary computed tomography and RF-IVUS performed at 12 months. 18 plaque regression, the increase of calcium may be interpreted as conversion of non-calcified to calcified plaque rather than a progression of the underlying atherosclerotic process. Imaging studies in patients with ACS as well as autopsy studies in sudden cardiac death patients have suggested less calcification in unstable plaques when compared with stable plaques, 23, 24 supporting the hypothesis that calcium may increase plaque stability. The absence of information on the distribution and localization of the observed calcification process prohibits a full understanding of the observed change in calcified tissue.
Radiofrequency intravascular ultrasonography defined changes in plaque phenotype
We observed in average 1.5 TCFAs as defined by RF-IVUS per patient in the proximal segment of non-IRAs. In a pathology study, TCFAs defined by histology have been shown to accumulate in the proximal 30 mm segments of the epicardial coronary arteries, 25 providing an explanation for the higher frequency of TCFAs in the present study compared with the only previous RF-IVUS study investigating non-IRA lesions. 26 Plaque phenotype analysis indicated infrequent changes throughout the study period, without evidence for transformation into higher risk plaque phenotypes. Most RF-IVUS defined TCFAs did not change their characteristics over time with a minority of 14% converting into a lower risk phenotype (P ¼ 0.15). In the only available study using serial intracoronary imaging in STEMI patients 26 who underwent treatment with the standard statin therapy during a follow-up duration of 13 months, the frequency of TCFAs increased over time (29%), providing indirect evidence for a hypothetical effect of high-intensity dose statin therapy, a finding which is hypothesis generating and warrants further investigation.
Limitations
The results have to be interpreted in the light of the following limitations. Firstly, the analysis was not based on a formal sample size consideration. Rather, it used data from 82 STEMI patients who were successfully enrolled as part of a substudy of a previously published randomized trial comparing two stent types in the setting of primary PCI. 12 In an exploratory analysis, the width of the actual 95% confidence interval of the difference in PAV suggests that there was 80% power to detect a difference of 0.94% from baseline to follow-up. Secondly, the number of patients included into the study of patients with acute myocardial infarction is considerably smaller compared with previously reported regression trials in patients with stable coronary artery disease. Thirdly, this was an observational study without control group, as we regarded the absence of high-intensity statin therapy as clinically not acceptable. Another limitation is that only selected patients underwent serial intracoronary imaging, as multi-vessel intracoronary imaging in the setting of STEMI is technically demanding and can only performed in stabilized patients with patent infarct-vessel. Therefore, these findings may not apply to unselected STEMI patients with different lesion phenotype. Finally, repeat imaging was scheduled at 13 months, which might affect the ability to detect long-term changes in plaque composition and phenotype.
Conclusion
The proximal segments of non-IRA of STEMI patients feature a highatherosclerotic plaque burden and harbour in average 1.5 TCFAs defined by RF-IVUS per patient. High-intensity rosuvastatin (40 mg/ day) therapy throughout 13 months was associated with a significant reduction of coronary atherosclerosis but no changes in RF-IVUS defined proportion of necrotic core or other plaque phenotypes. Regression of coronary atherosclerosis as a result of high-intensity statin therapy among STEMI patients may have important long-term clinical implications.
